At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Eloralintide (drug), Placebo (drug)
- How long the study runs
- Study runs about 27 months (dates as stated)
- About the drug or intervention
- Eloralintide — drug: Administered SC · Placebo — drug: Placebo administered SC
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 900
- Started
- 2026-02-09
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for osteoarthritis
- • Phase3 - 900 participants
- • The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with osteoarthritis
Where?
- • Bristol - Velocity Clinical Research, Bristol
- • Glasgow - FutureMeds Glasgow - CPS Research
- • London - FutureMeds - London
- • Newcastle - Futuremeds-Newcastle
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
- ✓Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
- ✓Have tried at least once to lose weight through diet but were unsuccessful
- ✓Have osteoarthritis of the knee and at least one of the following conditions:
- ✓Be over 50 years old
Who cannot take part
- ✗Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if...
- ✗Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy...
- ✗Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
- ✗Have an active knee infection
- ✗Have had within 90 days prior to screening:
See the full criteria
Where Is This Study? (8 UK sites)
Velocity Clinical Research, Bristol
Bristol BS8 2RA, United Kingdom
FutureMeds Glasgow - CPS Research
Glasgow G20 7BE, United Kingdom
FutureMeds - London
London NW10 2PB, United Kingdom
Futuremeds-Newcastle
Newcastle NE6 1SG, United Kingdom
Atlantic Medical
Penzance TR18 3DX, United Kingdom
Woodstock Bower Surgery
Rotherham S61 1AH, United Kingdom
Panthera Biopartners - Sheffield
Sheffield S2 5FX, United Kingdom
Panthera Clinic - York
York YO24 4LJ, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT
